



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/618,531	07/11/2003	Philip A. Furman	04674.105074 (TR1 1016)	6903
20786 7590 08/04/2009 KING & SPALDING 1180 PEACHTREE STREET, NE ATLANTA, GA 30309-3521				
EXAMINER JAGOE, DONNA A				
ART UNIT		PAPER NUMBER		
1614				
MAIL DATE		DELIVERY MODE		
08/04/2009		PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

10/618,531

Applicant(s)

FURMAN, PHILIP A.

Examiner

Donna Jagoe

Art Unit

1614

Period for Reply -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 30 March 2009.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-8 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-8 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO/SF/ICE)
- Paper No(s)/Mail Date 3/30/09 & 3/30/09
- 4) ☐ Interview Summary (PTO-413)
- Paper No(s)/Mail Date _____
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: _____

DETAILED ACTION

Applicants' arguments filed March 30, 2009 have been fully considered but they are not deemed to be persuasive. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. The following rejections and/or objections are either reiterated or newly applied. They constitute the complete set presently being applied to the instant application.

Claims 1-8 are pending in this application.

Claim Rejections - 35 USC § 103

Claims 1-8 are rejected under 35 U.S.C. 103(a) as being unpatentable over Schinazi et al. U.S. Patent No. 5,703,058 A and Thyagarajan U.S. Patent No. 6,589,570 B1.

Schinazi et al. teach **FTC** exhibits activity against Hepatitis B virus (HBV) (column 2, lines 40-41) and genetically engineered vaccine, **alpha interferon** effective for HBV (column 2, lines 46-55). Schinazi et al. further disclose that **L(-)FMAU** is an example of an antiviral agent that can be used in combination with the (-) enantiomer of FTC (column 6, lines 21-27) for the treatment of HBV infections in humans (column 3, lines 5-6).

It does not specifically teach all three agents to be combined into one agent to be administered, however Schinazi teach that the agents recited in claim 1 of the patent are to be administered in combination or in alternation with a second compound.

Schinazi teaches that FTC exhibits activity against **HBV** and alpha interferon is effective for **HBV** and that L(-)FMAU is an example of an antiviral agent that can be used in combination with the (-) enantiomer of FTC (column 6, lines 21-27) for the treatment of **HBV** infections in humans (column 3, lines 5-6).

One of ordinary skill in the art could have combined the elements as claimed by known methods and that in combination, each element merely would have performed the same function as it did separately, to treat or prophylax against HBV.

One of ordinary skill in the art would have recognized that the results of the combination were predictable.

The convenience of putting the β -L-FTC, L-FMAU and interferon together in one composition for the method of treating/prophylaxing against HBV, though perhaps a matter of great convenience, did not produce a new or different function and to those skilled in the art, the use of the old elements in combination would have been obvious. The selection of a known material based on its suitability for its intended use supported a *prima facie* obviousness determination in *Sinclair & Carroll Co. v. Interchemical Corp.*, 325 U.S. 327, 65 USPQ 297 (1945).

Schinazi et al. does not teach the β -L-FTC is substantially pure and it does not teach the many variations of interferon.

In general, stereoisomers/optical isomers are obvious from racemic mixtures. As legal authority the examiner cites *In re Adamson and Duffin*, 125 U.S.P.Q. 233. The case sets forth the requirements of patentability with regard to stereoisomers as follows:

1) The existence of a racemate is, in and of itself, sufficient to render obvious any individual stereoisomers contained within; no express suggestion of isomer separation is needed. See the first paragraph on page 235.

2) One skilled in the art expects that individual stereoisomers will differ significantly in physiological/pharmacological activity and toxicity, because living systems are chiral and thus preferentially process stereochemical configurations over others. See page 234, the third full paragraph and page 235, the fifth full paragraph on the page.

L-FTC is known from the recitation of its use for treatment of HBV in U. S. Patent 5,703,058. Consonant with the reasoning of *Adamson*, the existence of that racemate renders obvious any individual stereoisomers contained within, i.e. the R and S enantiomers recited instantly. Regarding the substantially pure form of β -L-FTC, Schinazi et al. teach that the β -L forms are specifically contemplated (column 7, line 64 to column 8, line 3). Schinazi teach that enantiomerically pure forms are used herein and the term enantiomerically enriched refers to a nucleoside composition that includes at least 95% to 98% of a single enantiomer of that nucleoside (column 6, lines 45-49). One skilled in the art would have been motivated to prepare additional useful compositions of the ranges taught by the prior art. While the reference is silent regarding the 90% by weight ratios, the difference in concentration will not support the patentability of subject matter encompassed by the prior art unless there is evidence indicating such concentration is critical. When the general conditions are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine

experimentation. In re Aller, 220 F.2d 45, 105 USPQ 233, 235 (CCPA 1955). In the absence of any criticality and/or unexpected results of the additional ranges claimed, the instant invention is considered obvious.

Regarding the method of use of alpha, beta and gamma interferon for the method of treating hepatitis B, Thyagarajan (quoting Lau et al., Gut. Suppl. 1991;547-562) recites in Table 1 (column 2), agents that have been studied and are successful in the treatment of HBV infection are *inter alia* Interferons such as Alpha interferon, Beta interferon and Gamma interferon.

It would have been made obvious to one of ordinary skill in art at the time it was made to employ the combination of β -L-FTC and L-FMAU and interferon for the treatment or prophylaxis of a human infected with hepatitis B virus motivated by the teaching of Schinazi et al. who recites that L(-)FMAU is an example of an antiviral agent that can be used in combination with the (-) enantiomer of FTC (column 6, lines 21-27) for the treatment of HBV infections in humans (column 3, lines 5-6) along with alpha interferon (column 2, lines 46-55) and the teaching of Thyagarajan who recites that Interferons such as Alpha interferon, Beta interferon and Gamma interferon are successful treatments for HBV.

Response to Arguments

Applicant cites KSR, 127 S. Ct., at 1741 as a basis for stating that "a patent composed of several elements is not proved obvious merely by demonstrating that each of its elements was, independently, known in the prior art". In response, KSR states


that since TSM test is based on helpful insights, namely, that a patent composed of several elements is not proved obvious merely by demonstrating that each of its elements was, independently, known in prior art, and that it can be important to identify reason that would have prompted person of ordinary skill in art to combine elements in manner claimed by new invention. In this case, each of the agents are individually disclosed to be used in combination for the treatment of hepatitis. It would have been obvious for one having ordinary skill in the art at the time the invention was made to employ interferon, L(-)FMAU and L-FTC in combination to treat the same disorder. In keeping with the flexible nature of the obviousness inquiry, *KSR Int'l Co. v. Teleflex Inc.*, 127 S. Ct. 1727, 1739 [82 USPQ2d 1385] (2007), ***the requisite motivation can come from any number of sources and need not necessarily be explicit in the art.*** See *Aventis Pharma Deutschland GmbH v. Lupin, Ltd.*, 499 F.3d 1293, 1301 [84 USPQ2d 1198] (Fed. Cir. 2007). Rather "it is sufficient to show that the claimed and prior art compounds possess a 'sufficiently close relationship ... to create an expectation,' in light of the totality of the prior art, that the new compound will have 'similar properties' to the old." *Id.* (quoting *Dillon*, 919 F.2d at 692). In this case, all of the agents are known individually to treat hepatitis B virus and the idea of combining them flows logically from their having been individually taught in the prior art

See in *In re Kerkhoven*, 626 F.2d 846, 205 USPQ 1069, at page 1072 (CCPA 1980):

It is prima facie obvious to combine two compositions each of which is taught by the prior art to be useful for the same purpose, in order to form a third composition which is to be used for the very same purpose. In re Susi, 58 CCPA 1074, 1079-80, 440 F.2d 442, 445, 169 USPQ 423, 426 (1971); In re Crockett, 47 CCPA 1018, 1020-21, 279


F.2d 274, 276-77, 126 USPQ 186, 188 (CCPA 1960). As this court explained in *Crockett*, the idea of combining them flows logically from their having been individually taught in the prior art.

Applicant states that the office action mischaracterizes the teachings of the cited art and states that Schinazi does not teach that L(-)FMAU is an example of an antiviral agent that can be used in combination with the (-) enantiomer of FTC (column 6, lines 21-27) for the treatment of HBV infections in humans (column 3, lines 5-6) along with alpha interferon (column 2, lines 46-55). In response, L(-)FTC is also known as



emtricitabine and the structure for emtricitabine is

. Schinazi



teach compounds that include the following;

wherein

R2 is H, Z is), Y is S. This structure is Emtricitabine (aka FTC). The patent teaches that this composition can be combined with agents such as L(-)FMAU and also with interferon (column 6, lines 21-27). Applicant further asserts that Schinazi does not

teach alpha interferon for treatment of HBV, but as a genetically engineered protein, that has also showed promise. In response, see patent claim 10 drawn to the composition wherein the second compound is interferon. Applicant asserts that Thyagarajan does not state that the interferons are successful in the treatment of HBV infection and further asserts that Thyagarajan states that interferons are agents that have been studied in the treatment of HBV infection and have limited success. In response, the limit on the success cited by Thyagarajan is because of prohibitive costs, side effects and limited accessibility. These limitations are not statements that the interferon is not effective in treating hepatitis B; it is a statement of the accessibility of the interferon. It does not teach away from the use of interferon. In response to applicant's argument that the examiner's conclusion of obviousness is based upon improper hindsight reasoning, it must be recognized that any judgment on obviousness is in a sense necessarily a reconstruction based upon hindsight reasoning. But so long as it takes into account only knowledge which was within the level of ordinary skill at the time the claimed invention was made, and does not include knowledge gleaned only from the applicant's disclosure, such a reconstruction is proper. See *In re McLaughlin*, 443 F.2d 1392, 170 USPQ 209 (CCPA 1971). Applicant's reliance on the post filing date reference, Osborn (April 2006), to allegedly provide evidence of non-obviousness is not persuasive. The determination of obviousness or non-obviousness must be based upon what was known in the art at the time the invention was made. See 35 U.S.C. § 103: "A patent may not be obtained...if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a

whole would have been obvious at the time the invention was made to a person having ordinary skill in the art".

Conclusion

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than **SIX MONTHS** from the mailing date of this final action.

Correspondence

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Donna Jagoe whose telephone number is (571) 272-0576. The examiner can normally be reached on Monday through Friday from 8:00 A.M. - 4:30 P.M..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ardin Marschel can be reached on (571) 272-0718. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Donna Jagoe /D. J./
Examiner
Art Unit 1614

July 28, 2009

/Ardin Marschel/
Supervisory Patent Examiner, Art Unit 1614